Project Engage: Oral PrEP Acceptability
A Phase II Acceptability Study of Oral Emtricitabine/Tenofovir Alafenamide (F/TAF) vs Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for the Prevention of HIV Acquisition in Adolescent Girls and Young Women (AGYW)
Sponsor: CONRAD
A PHASE2 clinical study on Acceptability of Health Care and Adherence, Medication, this trial is completed. The trial is conducted by CONRAD and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Sep 2022 — Sep 2023 [monthly]
Recruiting PHASE2
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CONRAD
- Eastern Virginia Medical School
- FHI 360
- Gilead Sciences
- United States Agency for International Development (USAID)
For direct contact, visit the study record on ClinicalTrials.gov .